Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 20,065 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures V. L.P. 5Am sold 20,065 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $150,487.50. Following the transaction, the insider directly owned 3,163,066 shares in the company, valued at $23,722,995. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Entrada Therapeutics Trading Down 3.1%

TRDA stock traded down $0.21 during trading hours on Friday, hitting $6.55. 219,912 shares of the stock traded hands, compared to its average volume of 134,864. The stock has a 50-day simple moving average of $7.68 and a 200 day simple moving average of $10.21. Entrada Therapeutics, Inc. has a one year low of $6.48 and a one year high of $21.79. The company has a market cap of $248.57 million, a P/E ratio of 8.09 and a beta of -0.11.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 5.84% and a net margin of 14.39%. The business had revenue of $8.75 million during the quarter, compared to analysts' expectations of $10.98 million. Analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS acquired a new position in shares of Entrada Therapeutics in the 4th quarter valued at $36,000. BNP Paribas Financial Markets acquired a new position in shares of Entrada Therapeutics in the 4th quarter valued at $57,000. Virtus ETF Advisers LLC acquired a new position in shares of Entrada Therapeutics in the 4th quarter valued at $68,000. AlphaQuest LLC acquired a new position in shares of Entrada Therapeutics in the 4th quarter valued at $70,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Entrada Therapeutics by 53,455.6% in the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock valued at $83,000 after purchasing an additional 4,811 shares during the period. Institutional investors and hedge funds own 86.39% of the company's stock.

Wall Street Analysts Forecast Growth

TRDA has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday, May 20th. Wall Street Zen raised Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, June 27th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $25.67.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.